A closer look at psilocybin and cognitive function
Psilocybin, the active compound in “magic mushrooms,” is gaining attention for its potential to treat depression, anxiety, and substance use disorders. But beyond its emotional and spiritual effects, researchers are now turning to a more practical question: how does psilocybin affect thinking, memory, and decision-making?
A recent meta-analysis published in Psychopharmacology reviewed 13 studies exploring the acute effects of psilocybin on cognitive function. The findings showed that people under the influence of psilocybin tend to respond more slowly to tasks and, in some cases, make more mistakes. The biggest impact was on reaction time, suggesting that thinking and responding become less efficient while the drug is active in the system.
Why executive functions matter
Executive functions—skills like working memory, attention, self-control, and cognitive flexibility—are central to how we function in daily life. These abilities also play a role in mental health recovery. For example, many psychiatric conditions involve difficulties with planning, impulse control, or focusing attention. If psilocybin worsens these abilities in the short term, it raises important safety and therapeutic questions.
Interestingly, the new research found that psilocybin’s impact wasn’t uniform. Accuracy in task performance wasn’t always significantly reduced. Many participants simply slowed down, rather than making frequent mistakes. Researchers suggest this may reflect broader effects on attention and motivation, rather than direct harm to higher-level thinking skills.
Are standard cognitive tests the right tool?
One of the most intriguing takeaways from this review is that standard lab tests may not fully capture what happens to cognition during a psychedelic experience. Traditional tasks, such as pressing a button when a light changes or identifying the color of a letter, may feel irrelevant or even frustrating to someone immersed in vivid visual distortions or deep emotional states.
This mismatch raises the possibility that current tests underestimate or misrepresent how psilocybin actually affects the mind. New methods, such as eye-tracking, real-world tasks, or even integrating neurofeedback, may provide a clearer picture.
Short-term slowdowns, long-term possibilities
The study focused only on the acute effects of psilocybin—typically within the first four hours of administration. But other research hints that once the immediate effects wear off, psilocybin may actually support cognitive growth. Some studies suggest improvements in creativity, problem-solving, and emotional regulation days or weeks after use.
Future studies will need to bridge this gap, exploring whether the initial slowdown is just a temporary trade-off for potential long-term benefits in mental health and brain function.
Moving forward in psychedelic science
The current findings highlight the importance of designing better tools for measuring cognition in altered states. Understanding psilocybin and cognitive function isn’t just about proving whether thinking is impaired—it’s about identifying how these changes fit into the bigger picture of healing, therapy, and personal growth.
As research continues, clinicians, patients, and scientists will be watching closely to see how psilocybin might both challenge and strengthen the mind.
References
- Yousefi, P., Lietz, M. P., O’Higgins, F. J., Rippe, R. C. A., Hasler, G., van Elk, M., & Enriquez‑Geppert, S. (2025). Acute effects of psilocybin on attention and executive functioning in healthy volunteers: a systematic review and multilevel meta-analysis. Psychopharmacology. Findings: slowed reaction times (Hedges’ g ≈ 1.13), non-significant effect on accuracy (Hedges’ g ≈ –0.45), dose dependence and methodological moderations LinkedIn+7SpringerLink+7PsyPost – Psychology News+7.
- Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–283. https://doi.org/10.1007/s00213-006-0457-5